The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysisSARS-CoV-2의 Delta 변종으로 인한 COVID-19에 대한 BNT162b2 mRNA 백신의 효과: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-02-012022-09-11 Journal: Inflammopharmacology [Category] COVID19(2023년), SARS, 변종, [키워드] 95% confidence interval administration B.1.617.2 BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine caused Chain Reaction COVID-19 database Delta delta variant determine Effectiveness eligible first dose identify indicated meta-analyses Meta-analysis meta-analysis model mRNA vaccine observational studies observational study Odds ratio of BNT162b2 offer Pfizer polymerase chain reaction Prevent Random-effects meta-analysis reduced reported reverse transcription Reverse transcription-polymerase chain reaction RT-PCR SARS-CoV-2 second dose strain systematic literature search systematic review the vaccine vaccination Vaccine variant was performed was used [DOI] 10.1007/s10787-021-00915-7 PMC 바로가기 [Article Type] Meta-Analysis
Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model햄스터 모델에서 SARS-CoV-2 B.1.1.28.2(P2) 변이체의 분리 및 D614G 변이체와의 병원성 비교Article Published on 2022-02-012022-09-11 Journal: Journal of infection and public health [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome B.1 B.1.1.28.2 body weight Body weight loss Brazil caused characterization Corona virus COVID-19 cases D614G variant demonstrated Efficacy genomic Genomic surveillance hamster hamsters Host immune response immune response India International isolate Isolation Lineage neutralization neutralized next generation sequencing P.2 variant P2 variant pathogenicity performed reduction reduction in respiratory respiratory tract returned rising SARS-CoV-2 SARS-CoV-2 genomic surveillance Sequencing sera Severe acute respiratory syndrome severe lung pathology Swab the vaccine United Kingdom variant variants Vero CCL81 cell Vero CCL81 cells viral replication virus virus isolation was performed weight loss [DOI] 10.1016/j.jiph.2021.12.009 PMC 바로가기 [Article Type] Article
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative reviewSARS-CoV-2 및 우려 변종에 대한 특성, 효능 및 효과에 대한 COVID-19 백신 비교: 서술적 검토Review Published on 2022-02-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse effects adverse event adverse events agency Alpha Analysis anaphylaxis AZD1222 benefit Beta bioRxiv BNT162b2 booster dose Characteristics Comparative analysis CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Critical death Delta Delta variants dose doses effective Effectiveness Efficacy Evidence Gamma Google Scholar Heterologous highest Hospitalization Immunity immunization Infection mass vaccination medRxiv mRNA mRNA vaccine mRNA vaccines mRNA-1273 myocarditis pandemic Phase III trials Prevent reduced reference Regulatory review Safe SARS-CoV-2 SARS-COV-2 infection seroneutralization severe acute respiratory syndrome Coronavirus severe COVID-19 Severe infection severe infections symptomatic symptomatic case symptomatic cases symptomatic COVID-19 the vaccine vaccination Vaccine Vaccines variant variants variants of concern waning immunity website [DOI] 10.1016/j.cmi.2021.10.005 PMC 바로가기 [Article Type] Review
Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency공통 가변성 면역 결핍증에서 항-SARS-CoV-2 백신의 면역원성Article Published on 2022-02-012022-09-12 Journal: Journal of Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] administration anti-SARS-CoV-2 vaccine antibodies antibody Antibody Response Antigen antigens Autoimmunity Cell cellular response characterized common common variable immunodeficiency COVID-19 COVID-19 vaccination COVID-19 vaccine CVID dose ELISA healthy control humoral Hypogammaglobulinemia IFN-γ immune immune response immunization immunodeficiency immunogenicity mechanism neutralizing antibody Patient patients Primary Immunodeficiency Primary immunodeficiency diseases prospectively studied Protective receiving SARS-CoV-2 second dose significantly lower subject T cell T cell response the vaccine therapy vaccination Vaccine variable was measured [DOI] 10.1007/s10875-021-01174-5 PMC 바로가기 [Article Type] Article
Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA VaccinationArticle Published on 2022-02-012022-11-15 Journal: JAMA Pediatrics [Category] COVID19(2023년), SARS, 진단, [키워드] age anti-SARS-CoV-2 antibody Antibody Response BNT162b2 Capacity Cohort cohort study collected Concentration convenience COVID-19 infection COVID-19 vaccine diagnosed Diagnosis domain exhibited first dose fraction functional Human human milk IgA IgA response IgG IgG antibody IgG response individuals induction Infant Infection lactating live SARS-CoV-2 median Messenger RNA microneutralization milk mRNA mRNA vaccination mRNA-1273 neutralization activity outcome parent parental parents participant polymerase chain prevaccination recruited robust SARS-CoV-2 second dose the vaccine vaccination Vaccine vaccine dose virus while [DOI] 10.1001/jamapediatrics.2021.4897 PMC 바로가기
Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients간 이식 환자에서 BNT162b2 메신저 RNA 백신 2회 투여 시 면역원성과 부작용Article Published on 2022-02-012022-09-12 Journal: Liver transplantation : official publication of th [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome administration Adverse adverse effect antibodies antibody Antibody Response BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine Control control group controls coronavirus defined dose Effect effective Efficacy geometric IgG IgG antibody titer immune response immune responses immunogenicity Immunoglobulin Immunosuppression infected with SARS-CoV-2 Liver transplantation median time men messenger Messenger RNA Mild mRNA neutralizing antibody occurred Patient patients positive positive antibody response RBD RBD IgG receiving recipient recipients reduced renal function responses RNA Safe SARS-CoV-2 second dose second vaccination shown study period the receptor-binding domain the vaccine therapy transplantation Vaccine women [DOI] 10.1002/lt.26366 PMC 바로가기 [Article Type] Article
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in ItalyBNT162b2 백신 후 다발성 경화증 환자의 Anti-Spike IgG: 이탈리아의 탐색적 사례 대조 연구Multicenter Study Published on 2022-02-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] adverse event AEs analyzed anti-spike antibodies antibodies antibody blood sample Blood samples BNT162b2 case-control study Clinical efficacy collected Community Comparisons condition Control COVID-19 COVID-19 vaccine described detect Disease-modifying therapies enrolled evaluated exploratory first dose HCW HCWs healthcare worker IgG Immunosuppressant immunosuppressants implication interquartile range IQR Italy median median and interquartile range Mild mild to moderate moderate multicenter Multiple multiple sclerosis observation Ocrelizumab of BNT162b2 one patient other treatment other treatments Patient patients patients treated performed Pfizer Pfizer-BioNTech receive receiving reduce reduced reported resolved respond scrutiny serological response severity the vaccine therapy treated treated patient treated patients Treatment treatment group vaccination vaccine dose Vaccine, BNT162b2. Vaccines Wilcoxon-Mann-Whitney [DOI] 10.1016/j.msard.2021.103415 PMC 바로가기 [Article Type] Multicenter Study
Willingness to Receive the COVID-19 Vaccination and the Psychological State of Japanese University Students: A Cross-Sectional StudyArticle Published on 2022-01-312022-10-29 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] Administered Anxiety association coronavirus disease COVID-19 COVID-19 pandemic depressive Effectiveness Efficacy and safety Factor identify investigated Japan Japanese Logistic regression analysis multivariate no difference participant Psychological Psychological distress psychological support questionnaire receive reported response significantly lower state strongly related Symptom the vaccine two groups university university student vaccination Vaccine was performed [DOI] 10.3390/ijerph19031654 PMC 바로가기 [Article Type] Article
Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China백신 유발 면역 및 중국에서 SARS-COV-2 전염병을 완화시키는 데 영향을 미치는 결과 조사Research Article Published on 2022-01-312022-09-10 Journal: BMC Medicine [Category] SARS, 변종, [키워드] age China Chinese compartmental model country Coverage COVID-19 delta variant develop Efficacy Epidemic Epidemics estimate herd immunity Immunity Infection initiated lack mitigate natural immunity natural infection provided reached reduce Result return SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 transmission severe disease SLIR model supplementary material tested the vaccine the vaccines Transmission unlikely vaccination Vaccination program Vaccine vaccine efficacy Vaccine-induced immunity [DOI] 10.1186/s12916-022-02243-1 PMC 바로가기 [Article Type] Research Article
Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort아르헨티나 코호트에서 SARS-CoV-2 계통 P.1 변이체에 대한 Gam-COVID-Vac 및 백신 유도 중화 반응 평가Article Published on 2022-01-312022-09-11 Journal: Vaccine [Category] SARS, 변종, 진단, 치료기술, [키워드] adverse event anti-S anti-S IgG Anti-spike Argentinean Cohort COVID-19 COVID-19 case detectable develop disease elicited evaluated Evidence evidence of form Gam-COVID-Vac humoral humoral immune response IgG antibodies IgG antibody immunized individual individuals induce Infection Isolation Lineage NAbs Nasopharyngeal swab neutralization potency neutralize Neutralizing Neutralizing antibodies neutralizing antibody no significant difference no significant differences P.1 P.1 variant participant Prevent receiving reported Safe SARS-CoV-2 SARS-CoV-2 lineage SARS-CoV-2 lineage P.1 second dose severe forms of COVID-19 significant differences Sputnik-V subject the vaccine Tolerance Transmission vaccinated individual vaccinated individuals variants variants of concern virus virus-neutralizing [DOI] 10.1016/j.vaccine.2021.12.027 PMC 바로가기 [Article Type] Article